Print

RhuDex® for the treatment of RA enters Phase I clinical trials

2005-05-09

RhuDex® is an orally administered small molecule with the intended principal indication rheumatoid arthritis (RA).
RA is a chronic, inflammatory disease affecting over 1% of the world's population and with a market value of 14 BUSD (2004).
In April 2002, Active Biotech signed a licensing agreement with Avidex regarding Active Biotech's patented CD80 antagonists. The agreement grants Avidex the exclusive right to further develop and to market the CD80 antagonists. For Active Biotech, the agreement entailed an initial payment in 2002 and eligibility for milestone payments totaling up to 5.8 MGBPas well as royalties on future sales.
The start of the Phase I clinical trial entitles Active Biotech to a minor milestone payment.
For further information regarding Active Biotech and our ongoing projects, visit our web site www.activebiotech.com.
Lund 9 May, 2005
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.

Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdf



Back